PCP
SLXP

Perimeter Capital Partners’s SALIX PHARMACEUTICALS LTD DEL SLXP Stock Holding History

Perimeter Capital Partners’s Portfolio SLXP Stock Details SLXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-5,176
Closed -$638K – 187
2014
Q2 		$638K Buy
5,176
+595
+13% +$65.8K 0.33% 136
2014
Q1 		$475K Buy
+4,581
New +$469K 0.24% 152
2013
Q3 		– Sell
-38,823
Closed -$2.57M – 285
2013
Q2 		$2.57M Buy
+38,823
New +$2.22M 0.5% 105

Other funds holding SLXP

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Perimeter Capital Partners's SLXP Position: Q3 2014 in Review

Perimeter Capital Partners sold out of SALIX PHARMACEUTICALS LTD DEL (SLXP) in Q3 2014, closing a stake of 5,176 shares — an estimated $638K sold.

Perimeter Capital Partners first reported a position in SLXP in Q2 2013 and held it in 3 quarters. The position peaked at $2.57M in Q2 2013. 348 funds tracked by Wall St. Rank hold SLXP as of Q3 2014.

  • Perimeter Capital Partners reported no remaining SALIX PHARMACEUTICALS LTD DEL position as of Q3 2014 after selling out during the quarter.
  • Perimeter Capital Partners sold 5,176 SALIX PHARMACEUTICALS LTD DEL shares in Q3 2014, an estimated $638K.
  • Perimeter Capital Partners first reported a position in SALIX PHARMACEUTICALS LTD DEL in Q2 2013 and held it in 3 quarters.
  • Perimeter Capital Partners's SALIX PHARMACEUTICALS LTD DEL position peaked at $2.57M in Q2 2013.
  • 348 funds tracked by Wall St. Rank held SALIX PHARMACEUTICALS LTD DEL as of Q3 2014.

Based on Perimeter Capital Partners's 13F filing for Q3 2014, filed 10 Nov 2014.